Glaukos Corporation
$10.8M 11,456 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Mesh Suture Inc
Mesh Suture Inc reported $10,847,155.72 across General Payments, Research, and Ownership to 86 physicians and teaching hospitals across 91 transactions.
- $10.8M Top 10% payer
- All-tracks total
- 91 Below-median volume
- Transactions
- 86 Below-median reach
- Recipients
- +$10.8K
- General Payments vs PY2023
Mesh Suture Inc reported $10,847,155.72 across all CMS Open Payments tracks (General + Research + Ownership) to 86 physicians and teaching hospitals in Program Year 2024 - ranking #158 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $11,155.72, averaging $126.1K per recipient.
How Mesh Suture Inc's $10.8M all-tracks total breaks down
Mesh Suture Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
36/100
Total payments
A
100/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer mesh-suture-inc Mesh Suture Inc
$10.8M · #158/1,925 · 0.1% industry · PY2024
- TOT $10.8M
- RANK #158
- SHARE 0.1%
- TXN 91
- RCP 86
- CAT 2
- GEN $11.2K
- ΔGEN +$10.8K
- TOP1 27.0%
- PY 2024
Volume peers
Nearest volume peer: Glaukos Corporation ($10.8M)
Mesh Suture Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Mesh Suture Inc's CMS-reported General Payments increased by $10.8K (+2849.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: MESH SUTURE INCPY2024: MESH SUTURE INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $378.29
- PY2024
- $11,155.72
What the Data Shows for Mesh Suture Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Mesh Suture Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 2 general-payment categories charted below, "Food and Beverage" is the largest at $6.4K across 80 transactions, 57.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Mesh Suture Inc's 2-category general-payment breakdown at $6.4K, 57.0% of the reported total.
How Mesh Suture Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $6.4K | 80 | 57.0% |
| Consulting Fee | $4.8K | 6 | 43.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $5,408.93 (48.5%) of $11,155.72 in this company's General Payments records across 80 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Mesh Suture Inc
The five named recipients with the highest reported General Payments from this company
- 1
Eric Pauli
$3,010.27 across 5 reported transactions
- 2
Vinayak Rohan
$1,800.00 across 2 reported transactions
- 3
Luis Garcia
$210.64 across 2 reported transactions
- 4
Charles Jehle
$194.01 across 1 reported transactions
- 5
Matthew Miller
$194.01 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Mesh Suture Inc ranks #158 of 1,925 by total payments (top 8% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,005 of 1,838 by HHI (bottom 45% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Cook Incorporated : $6.0M total payments, HHI 1081
- Grifols Shared Services North America, Inc. : $105.0K total payments, HHI 1080
- BioCryst Pharmaceuticals, Inc. : $326.1K total payments, HHI 1076
- Vektor Medical Inc. : $86.8K total payments, HHI 1068
- Magenta Medical Inc : $47.9K total payments, HHI 1068
- Galvanize Therapeutics, Inc : $228.2K total payments, HHI 1067
- Mesh Suture Inc (this company) : $11.2K total payments, HHI 1063
- Akebia Therapeutics Inc : $497.0K total payments, HHI 1056
- Omnia Medical, LLC : $2.0M total payments, HHI 1054
- Afaxys, Inc. : $17.3K total payments, HHI 1054
- ARKRAY USA, Inc. : $174.72 total payments, HHI 1052
- TransMedics, Inc. : $1.2M total payments, HHI 1045
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Mesh Suture Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Mesh Suture Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Mesh Suture Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Alafair Biosciences, Inc.
$10.8M 704 recipients
Compare payment profiles
TG Therapeutics, Inc.
$10.7M 12,185 recipients
Compare payment profiles
Janssen Scientific Affairs, LLC
$11.0M 9,610 recipients
Compare payment profiles
Ortho-Clinical Diagnostics, Inc.
$10.7M 232 recipients
Compare payment profiles
Sanofi-Aventis U.s. LLC
$10.7M 42,061 recipients
Compare payment profiles
Put this to use
Mesh Suture Inc ranks #158 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where Mesh Suture Inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Mesh Suture Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.